Company Profile
Evotec Stock Price, News & Analysis
- Ticker:
- EVO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Germany and listed in global markets with U
Stock performance
1.95 USD (-1.52%)
Close
Last updated: August 6, 2026
1.05B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, EVO closed down 1.52% at $1.95. No new same-company headline was identified in the current news window.
Company overview
Business overview
Evotec is a drug-discovery and development platform company that supports pharma partners with research services and collaborative programs.
Geographic Base and Sector Classification
Headquartered in Germany and listed in global markets with U.S. access, Evotec sits in discovery infrastructure.
Business Model Characteristics
The business combines service revenue, milestone economics, and collaborative drug-discovery partnerships.
Position Within the Biotechnology Landscape
Evotec is part of the biotech R&D infrastructure layer, where partner demand and platform execution matter most.
Future catalysts
Evotec's catalysts are discovery-partner deal flow, platform execution, and any asset monetization that improves the company’s capital structure. The market will watch whether the partnership engine can create more tangible value.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Evotec (EVO)?
Evotec (EVO) most recently closed at 1.95 USD, a -1.52% move versus the previous session.
What is the market cap of Evotec (EVO)?
Evotec currently has a market capitalization of 1.05B USD on BioPharmSignal.
What does Evotec do?
Evotec is a drug-discovery and development platform company that supports pharma partners with research services and collaborative programs.
On which exchange is EVO stock listed?
Evotec (EVO) is associated with NASDAQ, Germany and listed in global markets with U, Biopharma.
What is Evotec?
Evotec's catalysts are discovery-partner deal flow, platform execution, and any asset monetization that improves the company’s capital structure.
Which conditions is Evotec targeting with Evotec?
Evotec's catalysts are discovery-partner deal flow, platform execution, and any asset monetization that improves the company’s capital structure.
How does Evotec describe recent progress with Evotec?
Evotec's catalysts are discovery-partner deal flow, platform execution, and any asset monetization that improves the company’s capital structure.
What future catalysts are investors watching for Evotec?
Evotec's catalysts are discovery-partner deal flow, platform execution, and any asset monetization that improves the company’s capital structure. The market will watch whether the partnership engine can create more tangible value.